valu usd unless otherwis note
overshadow competit market turmoil
view execut strong sale oper leverag
guidanc improv promis metric quarter come
year howev see strong commerci perform
larg overshadow upcom competitor data competit
program decemb confer continu like
valuat growth increasingli diversifi late-stag pipelin
decreas depend complement franchis
model chang revis model reflect financi
report updat revenu expens guidanc increas
revenu estim non-gaap ep
base oper synergi beyond initi
expect howev lower expect net incom
ep respect owe
one-tim charg associ syntimmun acquisit
see note base report revenu date guidanc
rais fy forecast soliri pleas
see exhibit detail breakdown model chang price
dicerna rnai collabor posit build
complement-medi expertis concurr earn releas
today announc preclin collabor dicerna
deliv exclus world-wide licens
two preclin galxc rnai molecul includ option two
addit candid view collabor posit
round early-stag pipelin manag note call today
consid capac research stage
suggest galxc molecul receiv focus attent
go forward final addit compani pipelin paid
up-front addit equiti invest
undisclos mileston royalti payment
updat languag file detail inspect sale practic
japan file disclos recent administr
inspect japanes oper inspect japanes
author focus commun relat proper use
soliri ahu japan note inspect still earli
stage monitor situat close develop
upcom potenti catalyst initi gmg
studi initi subq studi
key competitor read-through roche/chugai regn
pnh dec rarx gmg top-
line result ahu trial
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
price target base sum-of-the-part
sotp methodolog estim probability-adjust
npv follow soliri sale pnh soliri
sale ahu strensiq sale
share kanuma sale lal-d soliri sale
mg soliri sale nmo
compani project cash posit
compani debt posit
price target support outperform rate
upsid scenario assum faster-than-
expect uptak metabol franchis
regulatori approv pnh clinic success
trial ahu
downsid scenario assum
approv pnh addit neg readout ahu
mg nmosd addit assum discount
soliri npv base earlier-than-anticip biosimilar
entri case expect stock trade base
valu discount soliri busi metabol
despit pnh patient competit like soliri
mg approv see declin soliri pnh sale
larg off-set expans ahu mg focu
long-term revenu expens guidanc amid intens
development competit field complement
inhibitor anticip restructur could help remov
near-term overhang stock follow manag
could help protect pnh ahu
market competitor see dose
regimen promis highli conveni though riski
development strategi present pk
dose use remain unclear
whether recycl strategi use extend half
life hold high concentr note
therapeut antibodi commerci
high dose though conced dose would
like seen conveni mani competitor
ip extens like fend soliri biosimilar
see recent composit matter formul
method use patent extend ip us
hold launch biosimilar anticip issuanc
similar patent eu extend protect
eu countri view biosimilar soliri near-term
upcom potenti catalyst initi
subq studi result
ahu studi adult pediatr pt pdufa
pnh feb eu approv
pnh mid regulatori file soliri nmosd
risk factor neg influenc valuat
rate includ develop setback includ
regulatori reject pnh neg readout
studi ahu posit develop progress
compani report capit market estim
chang model revenu expens expens expens incom incom expens incom incom non- non- exhibit incom statement
compani report capit market estim
compani report capit market estim
soliri pnh ahu lal-d mg nmo pnh ahu mg nmo valu stock dilut share outstand net market sum-of-the-part valuat
price target base sum-of-the-part sotp methodolog
estim probability-adjust npv follow soliri sale pnh soliri
sale ahu strensiq sale kanuma sale lal-d
share soliri sale mg soliri sale nmo
compani project cash posit compani debt
posit price target support outperform rate
risk rate price target
factor neg influenc valuat rate includ develop
set-back includ neg readout studi ahu posit develop
progress competitor complement program
alexion pharmaceut global fulli integr biopharmaceut compani
focus treatment rare diseas lead commerci product soliri eculizumab
human monoclon antibodi direct complement factor soliri approv
treatment paroxysm nocturn hemoglobinuria pnh atyp hemolyt urem
syndrom ahu gener myasthenia gravi three ultra-rar diseas caus
uncontrol complement activ alexion aim expand soliri neurolog
transplant disord conduct late-stag develop program neuromyel optica
nmo delay graft function dgf antibody-medi reject amr
alexion also market strensiq asfotas alfa enzym replac therapi ert indic
hypophosphatasia grant us approv octob eu approv
septemb approv japan juli addit
acquisit synageva alexion own kanuma sebelipas alfa ert treatment
lysosom acid lipas defici lal-d receiv eu us market approv
septemb decemb respect approv japan march
compani current develop next gener complement inhibitor
treatment pnh ahu potenti complement associ diseas
